| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5901802 | Growth Hormone & IGF Research | 2016 | 7 Pages |
Abstract
There were no significant differences in LVM/BSA or parameters of diastolic function in patients with a history of acromegaly treated for GHD as compared to those who were untreated. These data are reassuring with respect to cardiovascular safety with GH use after treatment for acromegaly, although further longer term study is necessary to evaluate the safety and efficacy of GH treatment in this population.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Pouneh K. Fazeli, Jonathan G. Teoh, Eleanor L. Lam, Anu V. Gerweck, Tamara L. Wexler, Eliza P. Teo, Brian M. Russell, Ronen Durst, David McCarty, Rory B. Weiner, Michael H. Picard, Anne Klibanski, Karen K. Miller,